Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

19.69 +0.39 (+2.02%)
Streaming Delayed Price Updated: 1:49 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,183
Open 19.50
Bid (Size) 19.67 (1)
Ask (Size) 19.71 (1)
Prev. Close 19.30
Today's Range 19.33 - 19.95
52wk Range 12.52 - 28.25
Shares Outstanding 46,982,485
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via Globe NewsWire
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga

Performance

YTD
-9.84%
-9.84%
1 Month
-1.94%
-1.94%
3 Month
-10.30%
-10.30%
6 Month
+3.80%
+3.80%
1 Year
+13.88%
+13.88%

More News

Read More
Analyst Ratings for uniQure
Via Benzinga
uniQure to Participate in Multiple Upcoming Industry Conferences in March
From uniQure Inc.
Via Globe NewsWire
Why Shares of uniQure Rose 14.61% on Wednesday
Via The Motley Fool
uniQure Stock Trying To Close In On Key Technical Measure
Via Investor's Business Daily
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via Globe NewsWire
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
From uniQure Inc.
Via Globe NewsWire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
From uniQure Inc.
Via Globe NewsWire
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
Via Benzinga
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
From uniQure Inc.
Via Globe NewsWire
3 Growth Stocks That Could Rocket Higher in 2023
Via The Motley Fool
Newly Approved Drugs In US Command Over $200,000 On An Average
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via Globe NewsWire
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
From uniQure Inc.
Via Globe NewsWire
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
From uniQure Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
Via Investor's Business Daily
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
Via Benzinga
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
From uniQure Inc.
Via Globe NewsWire
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
From uniQure Inc.
Via Globe NewsWire
uniQure: Q3 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.